rs104894538
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_002968.3(SALL1):c.967C>T(p.Gln323*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_002968.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- Townes-Brocks syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
- Townes-Brocks syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 52
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Townes-Brocks-branchiootorenal-like syndrome Pathogenic:1
- -
Townes syndrome Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in SALL1 are known to be pathogenic (PMID: 9973281, 16088922, 23069192). This variant has been observed in a family affected with an atypical form of Townes-Brock syndrome or TBS (PMID: 14755477). ClinVar contains an entry for this variant (Variation ID: 7434). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln323*) in the SALL1 gene. It is expected to result in an absent or disrupted protein product. -
Townes-Brocks syndrome 1 Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at